Onasemnogene Abeparvovec-xioi
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy Type I
Conditions
Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
Trial Timeline
Feb 10, 2020 → Dec 31, 2035
NCT ID
NCT04042025About Onasemnogene Abeparvovec-xioi
Onasemnogene Abeparvovec-xioi is a phase 3 stage product being developed by Novartis for Spinal Muscular Atrophy Type I. The current trial status is active. This product is registered under clinical trial identifier NCT04042025. Target conditions include Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Muscular Atrophy Type I were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04042025 | Phase 3 | Active |
| NCT03837184 | Phase 3 | Completed |
| NCT03461289 | Phase 3 | Completed |
| NCT03505099 | Phase 3 | Completed |
| NCT03381729 | Phase 1 | Terminated |
| NCT03306277 | Phase 3 | Completed |
| NCT03421977 | Pre-clinical | Active |
Competing Products
20 competing products in Spinal Muscular Atrophy Type I
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 35 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 42 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 36 |
| Elezanumab | AbbVie | Pre-clinical | 30 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 35 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 40 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 21 |
| Zolgensma | Novartis | Pre-clinical | 33 |
| BVS857 + Placebo | Novartis | Phase 2 | 35 |
| AVXS-101 | Novartis | Phase 1 | 29 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 50 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 30 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| branaplam | Novartis | Phase 1/2 | 32 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 47 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 40 |
| Risdiplam | Roche | Phase 1 | 29 |
| ATI355 | Novartis | Phase 1 | 29 |